Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

Shots: Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies Robert recapitulates data presented at ASCO…

BySaurabh ChaubeyOctober 9, 2023

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2023

Shots:The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory goutStarting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…

BySenior EditorApril 3, 2023

Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

PharmaShots’ Key Highlights of First Quarter 2023

Contact US

OUR INFORMATION

FOLLOW US